## **Correction:** *Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition*

Rogiers A, Pires da Silva I, Tentori C, et al Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. *JImmunother Cancer* 2021;**9**:e001931.

The affiliation of author Paola Queirolo was incorrectly listed. The correct affiliation is: Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e001931corr2. doi:10.1136/jitc-2020-001931corr2

